Header Logo

Connection

SRDAN VERSTOVSEK to Survival Rate

Back to Details
This is a "connection" page, showing publications SRDAN VERSTOVSEK has written about Survival Rate.
SRDAN VERSTOVSEK
Connection Strength
1.041
Survival Rate
  1. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma. 2019 07; 60(7):1767-1774.
    View in: PubMed
    Score: 0.063
  2. Management of Myelofibrosis-Related Cytopenias. Curr Hematol Malig Rep. 2018 06; 13(3):164-172.
    View in: PubMed
    Score: 0.060
  3. Prognostication and Initiation of Therapy in Polycythemia Vera: Do We Have it Right? Curr Hematol Malig Rep. 2017 12; 12(6):507-509.
    View in: PubMed
    Score: 0.058
  4. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017 08; 59:110-116.
    View in: PubMed
    Score: 0.056
  5. Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome. Leuk Res. 2017 08; 59:105-109.
    View in: PubMed
    Score: 0.056
  6. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017 02 22; 10(1):55.
    View in: PubMed
    Score: 0.055
  7. Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities. Leuk Res. 2015 Apr; 39(4):419-23.
    View in: PubMed
    Score: 0.048
  8. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Dec; 98(12):1865-71.
    View in: PubMed
    Score: 0.043
  9. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leuk Res. 2013 Nov; 37(11):1472-6.
    View in: PubMed
    Score: 0.043
  10. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010 Feb 11; 115(6):1131-6.
    View in: PubMed
    Score: 0.033
  11. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood. 2009 Apr 30; 113(18):4171-8.
    View in: PubMed
    Score: 0.031
  12. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008 Sep 01; 112(5):1628-37.
    View in: PubMed
    Score: 0.030
  13. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Leukemia. 2008 Jun; 22(6):1295-8.
    View in: PubMed
    Score: 0.029
  14. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 2002 Jul; 118(1):151-6.
    View in: PubMed
    Score: 0.020
  15. Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol. 2001 Aug; 114(2):290-5.
    View in: PubMed
    Score: 0.019
  16. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol. 2021 06; 193(5):1004-1008.
    View in: PubMed
    Score: 0.018
  17. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295.
    View in: PubMed
    Score: 0.017
  18. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1502-1511.
    View in: PubMed
    Score: 0.017
  19. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020 Mar; 7(3):e226-e237.
    View in: PubMed
    Score: 0.017
  20. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.
    View in: PubMed
    Score: 0.017
  21. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol. 2019 Jul; 98(7):1611-1616.
    View in: PubMed
    Score: 0.016
  22. A multimodality work-up of patients with Hypereosinophilia. Am J Hematol. 2018 11; 93(11):1337-1346.
    View in: PubMed
    Score: 0.015
  23. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
    View in: PubMed
    Score: 0.015
  24. Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica. 2017 09; 102(9):1511-1518.
    View in: PubMed
    Score: 0.014
  25. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol. 2016 Apr; 173(1):114-26.
    View in: PubMed
    Score: 0.013
  26. Outcomes of Allogeneic Hematopoietic Cell Transplantation in?Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant. 2016 Mar; 22(3):432-40.
    View in: PubMed
    Score: 0.013
  27. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015 Sep; 100(9):1139-45.
    View in: PubMed
    Score: 0.012
  28. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53.
    View in: PubMed
    Score: 0.012
  29. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):110-4.
    View in: PubMed
    Score: 0.011
  30. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod Pathol. 2014 May; 27(5):681-9.
    View in: PubMed
    Score: 0.011
  31. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013 Jun 13; 121(24):4867-74.
    View in: PubMed
    Score: 0.011
  32. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol. 2013 Mar; 88(3):219-24.
    View in: PubMed
    Score: 0.010
  33. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012 Jul; 97(7):1029-35.
    View in: PubMed
    Score: 0.010
  34. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011 Jan; 96(1):62-8.
    View in: PubMed
    Score: 0.009
  35. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood. 2010 Dec 23; 116(26):5818-23; quiz 6153.
    View in: PubMed
    Score: 0.009
  36. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 2009 Sep 10; 114(11):2232-5.
    View in: PubMed
    Score: 0.008
  37. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 01; 27(4):504-10.
    View in: PubMed
    Score: 0.008
  38. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 01; 112(5):1638-45.
    View in: PubMed
    Score: 0.008
  39. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006 Oct; 20(10):1767-73.
    View in: PubMed
    Score: 0.007
  40. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol. 2006 Jul; 134(1):58-60.
    View in: PubMed
    Score: 0.007
  41. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour. Br J Haematol. 2006 Aug; 134(3):341-3.
    View in: PubMed
    Score: 0.007
  42. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk Res. 2006 Dec; 30(12):1591-5.
    View in: PubMed
    Score: 0.006
  43. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Leuk Res. 2007 Feb; 31(2):139-45.
    View in: PubMed
    Score: 0.006
  44. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006 Mar 15; 106(6):1306-15.
    View in: PubMed
    Score: 0.006
  45. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006 Jul 01; 108(1):45-51.
    View in: PubMed
    Score: 0.006
  46. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood. 2006 Jan 15; 107(2):480-2.
    View in: PubMed
    Score: 0.006
  47. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005 Aug 01; 104(3):547-54.
    View in: PubMed
    Score: 0.006
  48. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer. 2005 May 15; 103(10):2099-108.
    View in: PubMed
    Score: 0.006
  49. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004 Sep 15; 104(6):1624-30.
    View in: PubMed
    Score: 0.006
  50. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):68-75.
    View in: PubMed
    Score: 0.006
  51. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer. 2003 Dec 15; 98(12):2636-42.
    View in: PubMed
    Score: 0.006
  52. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2003 Oct; 27(10):893-7.
    View in: PubMed
    Score: 0.005
  53. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003 Oct 01; 102(7):2379-86.
    View in: PubMed
    Score: 0.005
  54. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia. 2003 Jun; 17(6):1100-3.
    View in: PubMed
    Score: 0.005
  55. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 May 01; 97(9):2225-8.
    View in: PubMed
    Score: 0.005
  56. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 2002 Nov 01; 95(9):1923-30.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.